BIO 300 Non-Small Cell Lung Cancer Study

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerventricularcellradiationpatient
  Phrases that lowered it: subjectssafetyscreeninghistoryfev1
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Collaborators: 5 (lowers risk) · Design
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Drug's FAERS reports marked serious: 95.0% (raises risk) · Drug's FDA history
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports before start: 47566 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 9208 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer NCT03819387 · started 2019 · scored riskier than 44% of active trials completed
• An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) NCT01684111 · started 2013 · scored riskier than 64% of active trials completed
• BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) NCT04839471 · started 2021 · scored riskier than 59% of active trials completed
• BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I NCT00876460 · started 2009 · scored riskier than 14% of active trials completed
• An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2) NCT01683682 · started 2013 · scored riskier than 47% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.